Skip to content

Research at St Andrews

Effect of corneal cross-linking versus standard care on keratoconus progression in young patients: the KERALINK randomized controlled trial

Research output: Contribution to journalArticlepeer-review

Open Access permissions

Open

Author(s)

Keralink Trial Study Group, Daniel F P Larkin, Kashfia Chowdhury, Jennifer M Burr, Mathew Raynor, Matthew Edwards, Stephen J Tuft, Catey Bunce, Emilia Caverly, Caroline Doré

School/Research organisations

Abstract

PurposeTo examine the efficacy and safety of corneal cross-linking (CXL) for stabilization of progressive keratoconus.DesignObserver-masked, randomized, controlled, parallel-group superiority trial.ParticipantsSixty participants 10 to 16 years of age with progressive keratoconus, one eye of each deemed the study eye.MethodsThe study eye was randomized to either CXL plus standard care or standard care alone, with spectacle or contact lens correction as necessary for vision.Main Outcome MeasuresThe primary outcome was steep keratometry (K2) in the study eye as a measure of the steepness of the cornea at 18 months. Secondary outcomes included keratoconus progression defined as a 1.5-diopter (D) increase in K2, visual acuity, keratoconus apex corneal thickness, and quality of life.ResultsOf 60 participants, 30 were randomized to CXL and standard care groups. Of these, 30 patients in the CXL group and 28 patients in the standard care group were analyzed. Mean K2 in the study eye 18 months after randomization was 49.7 D (standard deviation [SD], 3.8 D) in the CXL group and 53.4 D (SD, 5.8 D) in the standard care group. The adjusted mean difference in K2 in the study eye was –3.0 D (95% confidence interval [CI], –4.9 to –1.1 D; P = 0.002), favoring CXL. Adjusted differences between groups in uncorrected and corrected vision favored eyes receiving CXL: –0.31 logarithm of the minimum angle of resolution (logMAR; 95% CI, –0.50 to –0.11 logMAR; P = 0.002) and –0.51 logMAR (95% CI, –1.37 to 0.35 logMAR; P = 0.002). Keratoconus progression in the study eye occurred in 2 patients (7%) randomized to CXL compared with 12 patients (43%) randomized to standard care. The unadjusted odds ratio suggests that on average, patients in the CXL arm had 90% (odds ratio, 0.1; 95% CI, 0.02–0.48; P = 0.004) lower odds of experiencing progression compared with those receiving standard care.ConclusionsCXL arrests progression of keratoconus in the majority of young patients. CXL should be considered as a first-line treatment in progressive disease. If the arrest of keratoconus progression induced by CXL is sustained in longer follow-up, particular benefit may be derived from avoiding a later requirement for contact lens wear or corneal transplantation.
Close

Details

Original languageEnglish
Number of pages11
JournalOphthalmology
VolumeIn Press
Early online date21 Apr 2021
DOIs
Publication statusE-pub ahead of print - 21 Apr 2021

    Research areas

  • Cornea, Cornea cross-linking, Keratoconus

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Population screening for glaucoma in UK: current recommendations and future directions

    Hamid, S., Desai, P., Hysi, P., Burr, J. M. & Khawaja, A. P., 3 Aug 2021, In: Eye. First Online, 6 p.

    Research output: Contribution to journalReview articlepeer-review

  2. Interpretation of change scores for the National Eye Institute Visual Function Questionnaire-25: the minimally important difference

    Burr, J. M., Cooper, D., Ramsay, C. R., Che Hamzah, J. & Azuara-Blanco, A., 18 May 2021, (E-pub ahead of print) In: British Journal of Ophthalmology.

    Research output: Contribution to journalArticlepeer-review

  3. Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS)

    TAGS Study Group, King, A. J., Hudson, J., Fernie, G., Kernohan, A., Azuara-Blanco, A., Burr, J., Homer, T., Shabaninejad, H., Sparrow, J. M., Garway-Heath, D., Barton, K., Norrie, J., McDonald, A., Vale, L., MacLennan, G. & Kousha, O., 12 May 2021, In: BMJ. 373, 11 p., n1014.

    Research output: Contribution to journalArticlepeer-review

  4. Trends in diabetic retinopathy screening attendance and associations with vision impairment attributable to diabetes in a large nationwide cohort

    Lawrenson, J. G., Bourmpaki, E., Bunce, C., Stratton, I. M., Gardner, P., Anderson, J. & EROS Study Group, Apr 2021, In: Diabetic Medicine. 38, 4, 11 p., e14425.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. Femtosecond laser-assisted cataract surgery versus phacoemulsification cataract surgery (FACT): a randomized noninferiority trial

    Day, A. C., Burr, J. M., Bennett, K., Bunce, C., Doré, C. J., Rubin, G. S., Nanavaty, M. A., Balaggan, K. S., Wilkins, M. R. & FACT trial group, Aug 2020, In: Ophthalmology. 127, 8, p. 1012-1019 8 p.

    Research output: Contribution to journalArticlepeer-review

  2. Can automated imaging for optic disc and retinal nerve fiber layer analysis aid glaucoma detection?

    Banister, K., Boachie, C., Bourne, R., Cook, J., Burr, J. M., Ramsay, C., Garway-Heath, D., Gray, J., McMeekin, P., Hernández, R. & Azuara-Blanco, A., May 2016, In: Ophthalmology. 123, 5, p. 930-938 9 p.

    Research output: Contribution to journalArticlepeer-review

  3. Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review

    Castillo, M. M., Mowatt, G., Elders, A., Lois, N., Fraser, C., Hernández, R., Amoaku, W., Burr, J. M., Lotery, A., Ramsay, C. R. & Azuara-Blanco, A., Feb 2015, In: Ophthalmology. 122, 2, p. 399-406 8 p.

    Research output: Contribution to journalArticlepeer-review

  4. Re Coster et al.: A comparison of lamellar and penetrating keratoplasty outcomes: a registry study (Ophthalmology 2014;121:979-87)

    Somner, J. E. A., Hardman-Lea, S., Bourne, R., Burr, J. & Shah, P., Jan 2015, In: Ophthalmology. 122, 1, p. e9-e10

    Research output: Contribution to journalLetterpeer-review

ID: 274063018

Top